Beyond ELSIs: Where to from Here? From "Regulating" to Anticipating and Shaping the Innovation Trajectory in Personalized Medicine

Pharmacogenomics

Volumn , Issue , 2013, Pages 405-428

  Özdemir, Vural ^a,b,c   Joly, Yann ^a   Kirby, Emily ^a   Avard, Denise ^a   Knoppers, Bartha M ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Data Enabled Life Sciences Alliance International DELSA Global   (United States)

Author keywords

Anticipatory ethics; Data intensive science; ELSI; Fourth paradigm science; Global bioethics; Global personalized medicine; Global technology governance; Pharmacogenomics; Public policy

Indexed keywords

EID: 84882913249     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-391918-2.00011-1     Document Type: Chapter

References (88)

1. O'Neill O. Broadening bioethics: clinical ethics, public health and global health. Twentieth Anniversary Lecture. Nuffield Council on Bioethics 2011, May 19.
2. Friend S. Thinking outside the genome. The Scientist 2011 (October). Available from: [Accessed February 29, 2012]. http://the-scientist.com/2011/10/01/opinion-thinking-outside-the-genome/ .
3. Nuffield Council on Bioethics. Medical Profiling and Online Medicine: The Ethics of Personalized Healthcare in a Consumer Age. Oxford: Nuffield Council on Bioethics 2.
4. James Lind Library 2003, Available from:, [Accessed February 29, 2012]. http://www.jameslindlibrary.org/about_us.html.
5. Garrod A.E. The incidence of alcaptonuria: a study in chemical individuality. Lancet 1902, 2:1616-1620.
6. Motulsky A.G. Drug reactions, enzymes and biochemical genetics. J Am Med Assoc 1957, 165:835-837.
7. Vogel F. Moderne problem der humangenetik. Ergeb Inn Med U Kinderheilk 1959, 12:52-125.
8. Kalow W. Pharmacogenetics. Heredity and the Response to Drugs 1962, W.B. Saunders Co., Philadelphia.
9. Schmeck H.M. Heredity linked to drug effects. New York Times October 10, 1962.
10. Vesell E.S., Page J.G. Genetic control of drug levels in man: antipyrine. Science 1968, 161:72-73.
11. Eichelbaum M., Spannbrucker N., Dengler H.J. Noxidation of sparteine in man and its interindividual differences. Arch. Pharmacol 1975, 287. R94.
12. Eichelbaum M., Spannbrucker N., Steincke B., et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979, 16:183-187.
13. Mahgoub A., Idle J.R., Dring L.G., et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2:584-586.
14. Reidenberg M.M. Individualization of drug therapy. Med Clin North Am 1974, 58:905-1162.
15. Ozdemir V., Pang T., Knoppers B.M., et al. Vaccines of the twenty-first century and vaccinomics: data-enabled science meets global health to spark collective action for vaccine innovation. OMICS 2011, 15(9):523-527.
16. Schofield P.N., Eppig J., Huala E., et al. Research funding. Sustaining the data and bioresource commons. Science 2010, 330(6004):592-593.
17. Suresh S. Moving toward global science. Science 2011, 333(6044). 802.
18. Science Metrix 30 years in science. Secular movements in knowledge creation. Science Metrix 2010, Available from:, [Accessed March 7, 2012]. http://www.science-metrix.com/30years-Paper.pdf.
19. European Commission Ethical, Legal and Social Aspects of the Life Science and the Technologies 1994, Available from:, [Accessed February 29, 2012]. http://cordis.europa.eu/elsa-fp4/home.html.
20. Ozdemir V., Knoppers B.M. From government to anticipatory governance. Responding to challenges set by emerging technologies and innovation. Governance for Health in the Twenty-first Century 2012, Springer, New York, in press. I. Kickbusch (Ed.).
21. World Economic Forum Global Risks 2012, [Accessed February 29, 2012]. http://reports.weforum.org/global-risks-2012/, seventh ed.
22. Hather G.J., Haynes W., Higdon R., et al. The United States of America and scientific research. PLoS One 2010, 5(8):e12203.
23. Rotimi C.N. Conceptual Framework of the Human Heredity and Health in Africa. Ethics and Genomics Research in Africa (EAGER-AFRICA) Conference Nov 28-29, 2011, Nigeria, Abuja, Available from:, [Accessed February 29, 2012]. http://eager-africa.com/ea/slide.php.
24. Hey T., Tansley S., Tolle K. The Fourth Paradigm: Data-Intensive Scientific Discovery 2009, Microsoft Research, Redmond, WA.
25. Ozdemir V., Smith C., Bongiovanni K., et al. Policy and data intensive scientific discovery in the beginning of the 21st century. OMICS 2011, 15(4):221-225.
26. Ozdemir V., Armengaud J., Dubé L., et al. Nutriproteomics and proteogenomics: cultivating two novel hybrid fields of personalized medicine with added societal value. Curr Pharmacogenomics Person Med 2010, 8(4):240-244.
27. Kaye J. From single biobanks to international networks: developing e-governance. Hum Genet 2011, 130(3):377-382.
28. Knoppers B.M. Consent to "personal" genomics and privacy. Direct-to-consumer genetic tests and population genome research challenge traditional notions of privacy and consent. EMBO Rep 2010, 11(6):416-419.
29. Howard H.C., Knoppers B.M., Borry P. Blurring lines. The research activities of direct-to-consumer genetic testing companies raise questions about consumers as research subjects. EMBO Rep 2010, 11(8):579-582.
30. Knoppers B.M., Avard D. "Principled" personalized medicine?. Personalized Medicine 2009, 6:663-667.
31. Nuremberg Code Trials of war criminals before the Nuremberg Military Tribunals under Control Council Law 1949, US Government Printing Office, Washington, 181-2.
32. Belmont Report Ethical principles and guidelines for the protection of human subjects of research. National Commission for the Protection of Human Subjects in Biomedical and Behavioral Research 1978, Department of Health, Education, and Welfare (DHEW) Publication No. (OS), 78-0012.
33. Beauchamp T.L., Childress J.F. Principles of Biomedical Ethics 2008, Oxford University Press, Oxford. sixth ed.
34. Probst-Hensch N., Tanner M., Kessler C., et al. Prevention-a cost-effective way to fight the non-communicable disease epidemic: an academic perspective of the United Nations High-level NCD Meeting. Swiss Med Wkly 2011, 141. w13266.
35. Ozdemir V. What to do when the risk environment is rapidly shifting and heterogeneous? Anticipatory governance and real-time assessment of social risks in multiply marginalized populations can prevent IRB mission creep, ethical inflation or underestimation of risks. Am J Bioeth 2009, 9(11):65-68.
36. Schicktanz S., Schweda M., Wynne B. The ethics of "public understanding of ethics"-why and how bioethics expertise should include public and patients' voices. Med Health Care Philos 2011 Mar 30, [Epub ahead of print].
37. Illinois White Paper Improving the System for Protecting Human Subjects: Counteracting Institutional Review Board (IRB) 2005, "Mission Creep". Urbana-Champagne, IL: Center for Advanced Study, University of Illinois.
38. Gunsalus C.K., Bruner E.M., Burbules N.C., et al. Mission creep in the institutional review board (IRB) world. Science 2006, 312(5779). 1441.
39. Knoppers B.M. Genomics and policymaking: from static models to complex systems?. Hum Genet 2009, 125(4):375-379.
40. Burca G. Proportionality and wednesbury unreasonableness: the influence of european legal concepts on UK law. European Public Law 1997, 561.
41. Lunshof J.E. From genetic privacy to open consent. Person Med 2006, 3:187-194.
42. Ostrom E. Collective action and the evolution of social norms. Journal Econ Perspectives 2000, 14(3):137-158.
43. Knoppers B.M., Chadwick R. Human genetic research: emerging trends in ethics. Nat Rev Genet 2005, 6(1):75-79.
44. Funtowicz S.O., Ravetz J.R. A new scientific methodology for global environmental issues. Ecological Economics: The Science and Management of Sustainability 1991, 137-152. Columbia University Press, New York. R. Costanza (Ed.).
45. Gibbons M., Limoges C., Nowotny H., et al. The new production of knowledge 1994, Sage, London.
46. Nowotny H., Scott P., Gibbons M. "Mode 2" revisited: the new production of knowledge. Minerva 2003, 41:179-194.
47. Faraj S., Kwon D., Watts S. Contested artifact: technology sensemaking, actor networks, and the shaping of the Web browser. Information Technology & People 2004, 17(2):186-209.
48. Fisher E., Mahajan R., Mitcham C. Midstream modulation of technology: governance from within. Bulletin of Science. Technology & Society 2006, 26(6):485-496.
49. Douma K.F., Karsenberg K., Hummel M.J., et al. Methodology of constructive technology assessment in health care. International Journal of Technology Assessment in Health Care 2007, 23(2):162-168.
50. Denis J.L., Lamothe L., Langley A., et al. Governance and health: the rise of the managerialism in public sector reform. Rev Salud Publica (Bogota) 2010, 12(Suppl 1):105-122.
51. Kickbusch I. Governance for health in the 21st century. A study conducted for the WHO Regional Office for Europe. Presented at the First meeting of the European Health Policy Forum for High-Level Government Officials March 2011, Andorra, Andorra la Vella, 9-11.
52. Guston D.H., Sarewitz D. Real-time technology assessment. Technol Soc 2002, 24:93-109.
53. Fisher E. Editorial overview: public science and technology scholars: engaging whom?. Sci Eng Ethics 2011, 17(4):607-620.
54. Guston D.H. Anticipatory Governance: A Strategic Vision for Building Reflexivity into Emerging Technologies. Presentation March 14, 2011, Resilience 2011, Arizona State University, Tempe, AZ.
55. Ommer R., Wynne B., Downey R., et al. Pathways to Integration 2011, Genome British Columbia GSEAC Subcommittee on Pathways to Integration, Vancouver, Available from:, [Accessed on February 29, 2012]. http://www.genomebc.ca/index.php/download_file/view/611/910/.
56. Barben D., Fisher E., Selin C., et al. Anticipatory governance of nanotechnology: foresight, engagement and integration. The Handbook of Science and Technology Studies 2008, 979-1000. MIT Press, Cambridge, MA. E.J. Hackett, O. Amsterdamska, M. Lynch, J. Wajcman (Eds.).
57. Owen R., Goldberg N. Responsible innovation: a pilot study with the U.K. Engineering and Physical Sciences Research Council. Risk Anal 2010, 30(11):1699-1707.
58. Joly Y., McClellan K., Knoppers B.M. Personalized vaccines and public health genomics: anticipating and monitoring the ELSIs. Curr Pharmacogenomics Person Med 2010, 8:5-8.
59. Landry R., Amara N., Pablos-Mendes A., et al. The knowledge-value chain: a conceptual framework for knowledge translation in health. Bull World Health Organ 2006, 84(8):597-602.
60. Daudelin G., Lehoux P., Abelson J., et al. The integration of citizens into a science/policy network in genetics: governance arrangements and asymmetry in expertise. Health Expect 2011, 14:261-271.
61. Lehoux P. Moving beyond our mutual ignorance. Or, how would engaging the public benefit the personalized medicine community?. Curr Pharmacogenomics Person Med 2011, 9(2):76-79.
62. Lavis J.N., Ross S.E., Hurley J.E., et al. Examining the role of health services research in public policymaking. Milbank Q 2002, 80:125-154.
63. Collinridge D. The Social Control of Technology 1980, St. Martin's Press, New York.
64. Guston D. Toward anticipatory governance 2007, Available from:, [Accessed February 29, 2012]. http://nanohub.org/resources/3270.
65. Reddy P.J., Jain R., Paik Y.K., et al. Personalized medicine in the age of pharmacoproteomics: a close up on India and need for social science engagement for responsible innovation in post-proteomic biology. Curr Pharmacogenomics Person Med 2011, 9(1):67-75.
66. Joly Y. Open source approaches in biotechnology: utopia revisited. Maine Law Review 2007, 59:386-431.
67. Knoppers B.M., Zawati M.H., Kirby E.S. Sampling populations of humans across the world: ELSI issues. Annual Review of Genomics and Human Genetics 2012 Mar 8, [Epub ahead of print].
68. Hewitt R.E. Biobanking: the foundation of personalized medicine. Current Opinion in Oncology 2011, 23(1):112-119.
69. Vaught J., Rogers J., Carolin T., et al. Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. JNCI Monographs 2011, 42:24-31.
70. World Health Organization (WHO) Genetic Databases Assessing the Benefits and the Impact on Human and Patient Rights 2003, Switzerland, Geneva.
71. Knoppers B.M. Biobanking: international norms. J Law Med Ethics 2005, 33(1):7-14.
72. Knoppers B.M. Of genomics and public health: building public "goods"?. Can Med Assoc J 2005, 173(10):1185-1186.
73. Prainsack B., Buyx A. Solidarity: reflection on an emerging concept in bioethics 2011, Nuffield Council on Bioethics, Swindon, UK.
74. Vegvari A., Welinder C., Lindberg H., et al. Biobank resources for future patient care: developments, principles and concepts. J Clin Res Bioeth 2011, 1(1):24.
75. Betsou F., Rimm D.L., Watson P.H., et al. What are the biggest challenges and opportunities for biorepositories in the next three to five years?. Biopreserv Biobanking 2010, 8(2):81-88.
76. Meslin E., Garba I. Biobanking and public health: is a human rights approach the tie that binds?. Hum Genet 2011, 130(3):451-463.
77. Murtagh M., Demir I., Harris J., et al. Realizing the promise of population biobanks: a new model for translation. Hum Genet 2011, 130(3):333-345.
78. Carlile P.R. Transferring, translating, and transforming: an integrative framework for managing knowledge across boundaries. Organ Sci 2004, 15(5):555-568.
79. Kuhn T. The Structure of Scientific Revolutions 1962, University of Chicago Press, Chicago. second ed.
80. Ravetz J.R. Usable knowledge, usable ignorance: incomplete science with policy implications. Sci Commun 1987, 9:87-116.
81. Ozdemir V., Fisher E., Dove E.S., et al. End of the beginning and public health pharmacogenomics: knowledge in "mode 2" and p5 medicine. Curr Pharmacogenomics Person Med 2012, 10(1):1-6.
82. Dandara C., Adebamowo C., de Vries J., et al. An idea whose time has come? An African foresight observatory on genomics medicine and data-intensive global science. Curr Pharmacogenomics Person Med 2012, 10(1):1-6.
83. Dove E.S. The genetic privacy carousel: a discourse on proposed genetic privacy bills and the co-evolution of law and science. Curr Pharmacogenomics Person Med 2011, 9(4):252-263.
84. Bourdieu P. Outline of a Theory of Practice 1977, Cambridge University Press, Cambridge.
85. Bourdieu P., Wacquant L. An invitation to reflexive sociology 1992, University of Chicago Press, Chicago.
86. Khoury M.J., Gwinn M., Yoon P.W., Dowling N., Moore C.A., Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?. Genet Med 2007, 9(1):665-674.
87. Dove E.S., Faraj S.A., Kolker E., Ozdemir V. Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action. Genome Med 2012, 4(11):91.
88. Ozdemir V. OMICS 2.0: A Practice Turn for 21(st) Century Science and Society. OMICS 2013, 17(1):1-4.